Sarepta Therapeutics (SRPT) Net Cash Flow Growth (3y) (2013 - 2026)
Sarepta Therapeutics (SRPT) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 32.17% |
| 10 | Sarepta Therapeutics | 1.72 Bn | 1.31 Bn | 622.04 Mn | -52.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.43% |
| Dec 31, 2025 | 66.55% |
| Sep 30, 2025 | -16.30% |
| Jun 30, 2025 | 40.22% |
| Mar 31, 2025 | 0.76% |
| Dec 31, 2024 | 20.50% |
| Sep 30, 2024 | -23.69% |
| Jun 30, 2024 | -30.11% |
| Mar 31, 2024 | 62.02% |
| Dec 31, 2023 | -82.78% |
| Sep 30, 2023 | -23.30% |
| Jun 30, 2023 | 45.84% |
| Mar 31, 2023 | -28.11% |
| Dec 31, 2022 | -38.41% |
| Sep 30, 2022 | 59.26% |
| Jun 30, 2022 | -86.38% |
| Mar 31, 2022 | -63.94% |
| Dec 31, 2021 | 47.53% |
| Sep 30, 2021 | 21.21% |
| Jun 30, 2021 | 51.33% |